BioAge Labs Inc. (NASDAQ:BIOA) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds.

On March 10, Citi maintained a Buy rating on BioAge Labs Inc. (NASDAQ:BIOA). The firm significantly increased its price target from $15 to $52, citing a compelling outlook as the company approaches proof-of-concept data for BGE-102.

Tonhom1009/Shutterstock.com

Citi also sees significant commercial potential for the therapy across multiple indications, including peak U.S. sales of $9.5B for atherosclerotic cardiovascular disease and $2B for diabetic macular edema, supporting a more optimistic view of the company’s long-term growth trajectory.

On February 25, Oppenheimer began coverage of BioAge Labs Inc. (NASDAQ:BIOA) with a $60 price target and an Outperform rating. The firm is quite positive about the company’s lead compound, BGE-102, which can inhibit the NLRP3 pathway. This has recently received a lot of attention due to the potential of the compound in the reduction of cardiovascular risk, especially after the positive Phase 2 results from Ventyx Biosciences.

Oppenheimer points out the critical differentiation of the company’s compound in comparison to other adjacent NLRP3 and Interleukin compounds.

BioAge Labs Inc. (NASDAQ:BIOA) is engaged in developing therapeutic product candidates for metabolic diseases. Its product portfolio includes an NLRP3 inhibitor in Phase 1 of clinical trial and BGE-102. It is also working on APJ agonists for obesity.

While we acknowledge the potential of BIOA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.